There are several specific inhibitors of EGFR including gefitinib, erlotinib and cetuximab, and others have been studied for the treatment of breast cancer including IBC in clinical trials[21], but results so far remain controversial and disappointing. Here, EGFR is linked to inflammatory breast carcinoma.